Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study

被引:0
|
作者
Si Wei Li
Hua Wang
Mei lian Liu
Hai Bo Zhang
Yan Qun Xiang
Xing Lv
Wei Xiong Xia
Mu Sheng Zeng
Hai Qiang Mai
Ming Huang Hong
Xiang Guo
机构
[1] the Affiliated Hospital of Guilin Medical College,Department of Radiation Oncology
[2] Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in Southern China, Department of Nasopharyngeal Carcinoma
[3] The Tumor Hospital of Yichang City,State Key Laboratory of Oncology in Southern China, Department of Hematologic Oncology
[4] Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in Southern China
[5] Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in Southern China, Department of GCP
[6] Sun Yat-sen University Cancer Center,undefined
来源
Medical Oncology | 2013年 / 30卷
关键词
Prospective study; Nasopharyngeal carcinoma; Prognosis; Metastasis; RKIP; Chemoradiotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this prospective study is to investigate the predictive and prognostic significance of the Raf kinase inhibitory protein (RKIP) in locoregionally advanced nasopharyngeal carcinoma (NPC). Immunohistochemical assays were performed to detect the RKIP protein expression of samples from 212 patients with locoregionally advanced NPC. All patients were assigned randomly into the inductive chemotherapy plus radiation therapy (IC + RT) group, the concurrent chemoradiotherapy (CCRT) group, the inductive chemotherapy plus concurrent chemoradiotherapy (IC + CCRT) group, and the radiation therapy alone (RT) group. The patients in the IC + RT group were treated with IC using 2–3 cycles of cisplatin (80 mg/m2) and fluorouracil (500 mg/m2), repeated every 3 weeks, followed by radiotherapy. Those in the CCRT group were treated with weekly cisplatin (40 mg/m2) for 6–7 cycles during radiotherapy. In the IC + CCRT group, the chemotherapy prior to radiation was similar to the cisplatin–fluorouracil regimen in the IC + RT group, whereas it cisplatin regimen was identical to that in the CCRT group. The results show that RKIP is an independent prognostic factor for 5-year distant metastasis–free survival (DMFS), overall survival (OS), and progression-free survival (PFS). Patients with high RKIP expression benefited more from reduced metastasis in the IC + RT and the IC + CCRT group, with improved OS and PFS in each treatment group compared with that among patients with low RKIP expression. In the high RKIP expression subgroup, chemotherapy combined with radiotherapy improved the DMFS when compared with the RT group, but this effect was not observed in the low RKIP expression subgroup. RKIP was predictive of distant metastasis with good sensitivity and specificity. Clinically, high RKIP expression inhibited distant metastasis in advanced NPC, and its detection might be used to predict distant metastasis with good sensitivity and specificity. The effect of chemotherapy on distant metastasis in combined chemoradiotherapy might be related to the RKIP expression level. Patients with high RKIP expression showed more improved OS and PFS than their low RKIP expression counterparts. Higher RKIP expression improves the DMFS of patients who receive inductive high-dose cisplatin-based chemoradiotherapy, with or without concurrent cisplatin. Low RKIP expression is also a predictive marker for cancer progression and metastasis, which could be used to stratify patients with high risk of metastasis and death.
引用
收藏
相关论文
共 50 条
  • [11] Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma
    Liu, Sai-Lan
    Sun, Xue-Song
    Chen, Qiu-Yan
    Liu, Ze-Xian
    Bian, Li-Juan
    Yuan, Li
    Xiao, Bei-Bei
    Lu, Zi-Jian
    Li, Xiao-Yun
    Yan, Jin-Jie
    Yan, Shu-Mei
    Li, Jian-Ming
    Bei, Jin-Xin
    Mai, Hai-Qiang
    Tang, Lin-Quan
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 163 : 26 - 34
  • [12] Effect of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy on Nutritional Status in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: A Prospective Observational Study
    Miao, J.
    Hu, C.
    Lin, S.
    Chen, X.
    Chen, Y.
    Zhong, Y.
    Jin, F.
    Lin, Q.
    Hu, X.
    Zhang, N.
    Wang, R.
    Wang, L.
    Wang, C.
    Zhu, M.
    Wu, H.
    Di, M.
    Huang, Y.
    Xie, C.
    Zhao, C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E334 - E334
  • [13] Locoregionally advanced nasopharyngeal carcinoma in childhood and adolescence: Analysis of 95 patients treated with combined chemotherapy and intensity-modulated radiotherapy
    Guo, Qiaojuan
    Cui, Xiaofei
    Lin, Shaojun
    Lin, Jin
    Pan, Jianji
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E665 - E672
  • [14] Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
    Mu, Xiaoli
    Liu, Hongyan
    Wu, Juan
    Chen, Shi
    Peng, Xingchen
    Wang, Jingjing
    Wei, Zhigong
    He, Ling
    Liu, Jiyan
    Lu, Zejun
    Su, Yonglin
    [J]. AGING-US, 2022, 14 (16): : 6727 - 6739
  • [15] Anlotinib combined with induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase II study.
    Jiang, Feng
    Chen, Xiaozhong
    Liu, Tongxin
    Qin, WeiFeng
    Huang, Shuang
    Cao, Caineng
    Jin, Ting
    Jin, Qifeng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18071 - E18071
  • [16] Preliminary results of a phase III randomized study comparing chemotherapy neoadjuvantly or concurrently with radiotherapy for locoregionally advanced nasopharyngeal carcinoma
    Tingting Xu
    Chaosu Hu
    Guopei Zhu
    Xiayun He
    Yongru Wu
    Hongmei Ying
    [J]. Medical Oncology, 2012, 29 : 272 - 278
  • [17] Preliminary results of a phase III randomized study comparing chemotherapy neoadjuvantly or concurrently with radiotherapy for locoregionally advanced nasopharyngeal carcinoma
    Xu, Tingting
    Hu, Chaosu
    Zhu, Guopei
    He, Xiayun
    Wu, Yongru
    Ying, Hongmei
    [J]. MEDICAL ONCOLOGY, 2012, 29 (01) : 272 - 278
  • [18] Effect of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy on nutritional status in locoregionally advanced nasopharyngeal carcinoma patients: A prospective observational study.
    Miao, Jingjing
    Hu, Chaosu
    Lin, Shaojun
    Chen, Xiaozhong
    Chen, Yuan Yuan
    Zhong, Yahua
    Jin, Feng
    Lin, Qin
    Hu, Xuefeng
    Zhang, Ning
    Wang, Rensheng
    Wang, Lin
    Wang, Cong
    Zhu, Manyi
    Wu, Haijun
    Di, Muping
    Huang, Yuqing
    Xie, Conghua
    Zhao, Chong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [19] A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: Updated long-term survival outcomes
    Xu, Tingting
    Zhu, Guopei
    He, Xiayun
    Ying, Hongmei
    Hu, Chaosu
    [J]. ORAL ONCOLOGY, 2014, 50 (02) : 71 - 76
  • [20] Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma
    Wu, Mingyao
    Ou, Dan
    He, Xiayun
    Hu, Chaosu
    [J]. ORAL ONCOLOGY, 2017, 73 : 118 - 123